You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The first six months of the year have already seen some major deals announced, including big acquisitions by Abbott and Thermo Fisher Scientific.
Prequalification now enables procurement in numerous countries within sub-Saharan Africa that have regulations requiring this type of oversight.
The prototype showed biases at low virus concentrations and the researchers raised concerns over use of whole blood versus plasma HIV RNA as a biomarker.
Following a partial response to Abbott's request to audit its books, Alere said it is confident the transaction will be completed.
The GenomeWeb Index fell 1 percent in April, outperforming the Nasdaq, but falling significantly short of the performance of the Nasdaq Biotech Index.
Alere also said that some of its creditors have agreed to waive defaults arising from its delay in filing its 2015 earnings report, though others have already filed default notices.
The company said its financial plan contemplates the acquisition of both St. Jude and Alere, which is under investigation for its foreign business practices.
Abbott reported Diagnostics sales of $1.12 billion, up 2 percent on a reported basis and 7 percent excluding foreign currency effects.
The companion test will let doctors identify the best treatment for CLL patients with 17p deletions, a subset that has historically lacked therapeutic options.
The test, which was previously approved for CLL prognosis, is now cleared for use in identifying patients who may benefit from AbbVie and Genentech's Venclexta.
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.